en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2020
vol. 95
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Artykuł oryginalny

Fibroblast growth factor 23 and α-Klotho serum concentration did not differ between children with autosomal dominant polycystic kidney disease and healthy controls

Marta Kostrzewa
1
,
Kamil W. Faltin
1
,
Monika Pawlak-Bratkowska
2
,
Piotr Grzelak
3
,
Alina Niewiadomska
4
,
Marcin Tkaczyk
2, 5

  1. Department of Paediatrics, Preventive Cardiology and Immunology of Developmental Age, Student Study Group, Medical University of Lodz, Lodz, Poland
  2. Department of Paediatrics, Immunology and Nephrology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
  3. Department of Diagnostic Imaging, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
  4. Laboratory Diagnostics Center, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
  5. Division of Didactics in Paediatrics, Medical University of Lodz, Lodz, Poland
Pediatr Pol 2020; 95 (2): 80–85
DOI: https://doi.org/10.5114/polp.2020.97092
Data publikacji online: 2020/07/10
Plik artykułu:
- Fibroblast growth.pdf  [0.53 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Cadnapaphornchai MA. Autosomal dominant polycystic kidney disease in children. Curr Opin Pediatr 2015; 27: 193-200.
2. Pavik I, Jaeger P, Kistler AD, et al. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 2011; 79: 234-240.
3. Seeman T, Dušek J, Vondrichová, et al. Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 2003; 8: 107-110.
4. Cadnapaphornchai MA, McFann K, Strain JD, et al. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 2008; 74: 1192-1196.
5. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747.
6. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
7. Małyszko J. Klotho protein and chronic kidney disease [Białko Klotho a przewlekła choroba nerek]. Forum Nefrol 2009; 2: 69-73.
8. Liu D, Alvarez-Elías AC, Wile B, et al. Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: a cross-sectional study. BMC Nephrology 2017; 18: 204.
9. Fick-Brosnahan GM, Tran ZV, Johnson AM, et al. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 2001; 39: 1654-1662.
10. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2015; 88: 17-27.
11. Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993.
12. Ravine D, Sheffield LJ, Danks DM, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-827.
13. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease. J Am Soc Nephrol 2005; 16: 2205-2215.
14. Koh N, Fujimori T, Nishiguchi S, et al. Severely Reduced Production of Klotho in Human Chronic Renal Failure Kidney. Biochem Biophys Res Commun 2001; 280: 1015-1020.
15. Salwa I, Rashed L. Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. Int Urol Nephrol 2009; 41: 163-169.
16. Sari F, Inci A, Dolu S, et al. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease. J Investig Med 2017; 65: 358-362.
17. Lindblad YT, Olauson H, Vavilis G, et al. The FGF23–Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease – a prospective cohort study. Pediatr Nephrol 2018; 33: 147-157.
18. Wan M, Smith C, Shah V, et al. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Nephrol Dial Transplant. 2013; 28: 153-161.
19. Sawires HK, Essam RM, Morgan MF, Mahmoud RA. Serum Klotho: Relation to Fibroblast Growth Factor-23 and Other Regulators of Phosphate Metabolism in Children with Chronic Kidney Disease. Nephron 2015; 129: 293-299.
20. Wesseling-Perry K, Tsai EW, Ettenger RB, et al. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant 2011; 26: 3779-3784.
21. Bacchetta J, Dubourg L, Harambat J, et al. The Influence of Glomerular Filtration Rate and Age on Fibroblast Growth Factor 23 Serum Levels in Pediatric Chronic Kidney Disease. J Clin Endocrinol Metab 2010; 95: 1741-1748.
22. Viaene L, Bammens B, Meijers BKI, et al. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol Dial Transplant 2012; 27: 2017-2022.
23. Portale AA, Wolf MS, Messinger S, et al. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol 2016; 11: 1989-1998.
24. Bożentowicz-Wikarek M, Kocełak P, Chudek J. FGF-23 as a marker of impaired glomerular filtration rate [FGF-23 jako marker upośledzenia filtracji kłębuszkowej]. Nephrol Dial Pol 2011; 15: 53-56.
25. Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D. Fibroblast growth factor 23 and Klotho serum levels in healthy children. Bone 2014; 66: 8-14.
26. Pavik I, Jaeger P, Ebner L, et al. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013; 28: 352-359.
27. Silva AP, Mendes F, Pereira L, et al. Klotho levels: association with insulin resistance and albumintocreatinine ratio in type 2 diabetic patients. Int Urol Nephrol 2017; 49: 1809-1814.
28. Seiler S, Wen M, Roth HJ, et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2012; 83: 121-128.
29. Sugiura H, Tsuchiya K, Nitta K. Circulating levels of soluble -Klotho in patients with chronic kidney disease. Clin Exp Nephrol 2011; 15: 795-796.
30. Akiyama K, Mochizuki T, Kataoka H, et al. Fibroblast growth factor 23 and soluble Klotho in patients with autosomal dominant polycystic kidney disease. Nephrology 2017; 22: 848-853.
31. Eckardt KU, Möllmann M, Neumann R, et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989; 84: 1160-1166.
32. Hu MC, Shi M, Zhang J, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24: 3438-3450.
33. Yamazaki Y, Imura A, Urakawa I, et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 2010; 398: 513-518.
34. Shibata K, Fujita S, Morita, et al. Association between circulating fibroblast growth factor 23, -Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One 2013; 8: e73184.
35. Pavik I, Jaeger P, Ebner L, et al. Soluble Klotho and autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7: 248-257.
36. Devaraj S, Syed B, Chien A, Jialal I. Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol 2012; 137: 479-485.
37. Akimoto T, Shiizaki K, Sugase T, et al. The relationship between the soluble Klotho protein and the residual renal function among peritoneal dialysis patients. Clin Exp Nephrol 2012; 16: 442-447.
38. Wesseling-Perry K, Pereira RC, Wang H, et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517.
39. Van Husen M, Fischer AK, Lehnhardt A, et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010; 78: 200-206.
40. Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: tertiary ‘hyper-phosphatoninism’? Kidney Int 2006; 70: 1486-1494.
Copyright: © 2020 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.